Drugs /

gvax cancer vaccine

Back to Drugs List

Overview

NCI Definition [1]:
An autologous or allogeneic cell vaccine comprised of tumor cells which have been lethally irradiated and genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone which plays a key role in stimulating the body's immune response to vaccines. GM-CSF may stimulate the body's immune system against tumor cells by attracting and enhancing the activation of antigen-presenting cells (APCs), such as dendritic cells (DCs). This promotes antigen presentation to T-lymphocytes and induces a cytotoxic T-lymphocyte (CTL) response against cells expressing tumor-associated antigens (TAAs).

Clinical Trials

View Clinical Trials for gvax cancer vaccine

Gvax cancer vaccine has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating gvax cancer vaccine, 2 are phase 1 (2 open).

Colorectal carcinoma and neuroblastoma are the most common diseases being investigated in gvax cancer vaccine clinical trials [2].

Drug Details

Synonyms [2]:
gm-csf-secreting lethally irradiated tumor cell vaccine, gvax tumor vaccine
NCIT ID [1]:
C1978

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.